AlphaQuest’s Rapport Therapeutics RAPP Stock Holding History

AlphaQuest’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,754	Closed	-$114K	–	2195
2025 Q4	$114K	Buy	+3,754	New	+$104K	0.01%	1696

Other funds holding RAPP

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGV

TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

AlphaQuest's RAPP Position: Q1 2026 in Review

AlphaQuest sold out of Rapport Therapeutics (RAPP) in Q1 2026, closing a stake of 3,754 shares — an estimated $114K sold.

AlphaQuest first reported a position in RAPP in Q4 2025 and held it in 1 quarter. The position peaked at $114K in Q4 2025. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

AlphaQuest reported no remaining Rapport Therapeutics position as of Q1 2026 after selling out during the quarter.
AlphaQuest sold 3,754 Rapport Therapeutics shares in Q1 2026, an estimated $114K.
AlphaQuest first reported a position in Rapport Therapeutics in Q4 2025 and held it in 1 quarter.
AlphaQuest's Rapport Therapeutics position peaked at $114K in Q4 2025.
147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.